Alterity Therapeutics Ltd: Form 20-F for the period ended Jun 30, 2018
Filed with the SEC on Aug 31, 2018 and accepted by EDGAR at Aug 31, 2018, 08:36 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2017-07-01 to 2018-06-30 | AUD 201.2k | ifrs-full:Revenue |
| Income tax | 12 months2017-07-01 to 2018-06-30 | AUD 0 | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months2017-07-01 to 2018-06-30 | −AUD 8.3m | ifrs-full:ProfitLoss |
| Operating cash flow | 12 months2017-07-01 to 2018-06-30 | −AUD 6.2m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months2017-07-01 to 2018-06-30 | AUD 62.4k | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | At period end2018-06-30 | AUD 15.2m | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2018-06-30 | AUD 18.7m | ifrs-full:CurrentAssets |
| Total assets | At period end2018-06-30 | AUD 18.7m | ifrs-full:Assets |
| Current liabilities | At period end2018-06-30 | AUD 2.6m | ifrs-full:CurrentLiabilities |
| Total liabilities | At period end2018-06-30 | AUD 2.6m | ifrs-full:Liabilities |
| Shareholders' equity | At period end2018-06-30 | AUD 16.1m | ifrs-full:Equity |
| Shares outstanding | At period end2018-06-30 | 533,891,470 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001144204-18-047425. Last ingested by Listed: Oct 30, 2026, 06:15 ET. Listed shows no prices and gives no investment advice.